Medicine
Yupelri 175 mcg/3 mL inhalation solution
Yupelri 175 mcg/3 mL inhalation solution is a prescription medicine containing Revefenacin for inhalation use, marketed by Viatris Specialty, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store YUPELRI in the protective foil pouch. • Store at room temperature from…
Key facts
- Active ingredient (INN)
- Revefenacin
- Brand
- Yupelri
- Strength
- 175 mcg/3 mL
- Dosage form
- Inhalation solution
- Route
- Inhalation
- Packs
- 30 pouches
- Marketing authorisation holder
- Viatris Specialty
- Manufacturer
- Viatris Specialty
- Origin register
- US FDA, United States
- Storage
- Store YUPELRI in the protective foil pouch. • Store at room temperature from 68°F to 77°F (20°C to 25°C), excursions permitted from 59°F to 86°F (15°C to 30°C). Protect from direct sunlight and excessive heat.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 3 December 2018
- Identifiers
- RxCUI 2102779, 2102784DailyMed set ID 6dfebf04-7c90-436a-9b16-750d3c1ee0a6NDC 49502-806Application NDA210598
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 30 pouch in 1 carton / 1 vial, single-dose in 1 pouch / 3 mL in 1 vial, single-dose | 49502-806-93 | Viatris Specialty | 3 December 2018 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 9 November 2018 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Revefenacin is an anticholinergic indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). It is available as inhalation solution. MedsAcross supplies Revefenacin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about RevefenacinFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- YUPELRI prescribing information (Viatris Specialty) · U.S. National Library of Medicine, DailyMed
Need Yupelri 175 mcg/3 mL inhalation solution for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.